The purpose of this study is to understand if small proteins found on the surface of myeloma cells (called CXCR4, CD47, and beta 2 adrenergic receptors) can predict how patients will respond to chemotherapy-treatment and if a small molecule inside the myeloma cells (called Pim kinase) can be used as a treatment target for myeloma. A sample from the bone marrow biopsy (a small amount of tissue removed from the body for laboratory testing) and aspirate (a small amount of fluid is removed from the body for laboratory testing) that you had done before you entered this study will be provided for research purposes. A small amount of the patient's bone marrow samples will be sent to our research laboratory to measure the CXCR4, CD47, beta 2- adrenergic receptor and the Pim kinase on the cells. Some of the cells will be grown in the lab and tested to measure the responses to new treatment agents. The researchers will check your medical records to gather information about you are responding to treatment, your cell counts and your laboratory data. Participation in the study will include 1 visit at MUSC at the same time as you are having the bone marrow biopsy procedure. The study doctor and his research staff may reference your medical records for information for up to five years after this study visit.
This study is for subjects with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has returned after treatment or did not respond to earlier treatment. The purpose of this study is to compare pegylated liposomal doxorubicin (PLD; a standard chemotherapy) to PLD in combination with VTX-2337 (a new type of drug that stimulates the immune system) to see if it helps cancer tumors stop growing or shrink, and if it helps women with these types of cancer live longer. PLD is an FDA-approved treatment for women with ovarian cancer. In prior studies, approximately 15–20% of women who received PLD for relapsed ovarian cancer experienced a temporary shrinkage or disappearance of their tumor. VTX 2337 is an experimental drug (not approved by the Food and Drug Administration, FDA) that stimulates the immune system and may help the body kill cancer cells. The combination of PLD plus VTX-2337 has been evaluated in a previous study of 13 patients. The study is still ongoing, but so far there is evidence that PLD + VTX-2337 may temporarily stop some patients’ tumors from growing (this happened in 6 patients), or it may help cancer tumors temporarily shrink and/or disappear (this happened in 1 patient).
In addition to the treatment part of this study, the researchers plan to test samples of your tumor and some of your blood. You cannot participate in this study if you do not agree to provide these specimens for this research. The purpose of this research is to examine the impact the study drugs have on tumor tissue and specific blood cells and substances.
Lastly, researchers want to know if one's genes (DNA) affect how the body responds to the experimental medication or how one's body breaks it down. Subjects will receive the study drugs as long as there is evidence that their tumor is not growing and they are not experiencing unacceptable side effects.
This study is for subjects with prostate cancer. The purpose of this study is to compare two methods of delivering high dose radiation to the prostate to see if the effects of the treatments are similar. Both methods have been studied previously and are considered promising treatment approaches. Screening procedures will be completed to ensure that subjects are eligible to participate in this study. If a subject is eligible and does agree to participate in this study, he will be assigned to 1 of 2 groups randomly. If subjects are in group 1 (often called "Arm 1"), they will receive radiation therapy two days a week over two and a half weeks, for a total of 5 treatments. If they are in group 2 (often called "Arm 2"), they will receive radiation therapy once daily, 5 days a week, Monday through Friday, for a total of 12 treatments over two and a half weeks. When treatment is finished subjects will need tests and procedures every 3 months for the first 2 years following the start of radiation, every 6 months for years 3, 4, and 5, and then annually.
This study is for patients that have a brain tumor, called a glioblastoma or gliosarcoma, which has become worse after previous treatment. The purpose of this study is to determine whether adding radiation to bevacizumab is more effective than using bevacizumab alone to treat recurrent glioblastomas.
In this trial patients will be randomly assigned to receive either bevacizumab alone or bevacizumab and radiation therapy.If you are in Group 1, you will be asked to take bevacizumab alone every two weeks as long as it is working and there are no intolerable side effects. If patients are assigned to Group 2, he/she will take bevacizumab 2 weeks before radiation therapy, during radiation therapy, and then every 2 weeks after radiation therapy as long as it is working and there are no intolerable side effects. The radiation will be given to participants over 2 weeks. Participants will be followed every 8 weeks while on treatment and then also if participants are removed from protocol treatment. Follow-up will continue every 8 weeks for 1 year, then every 6 months for 1 year, then annually.
This is not a treatment study. The Hollings Cancer Center Tissue Biorepository, (HCCTB), provides investigators with a centralized infrastructure to promote biomedical research involving the use and study of human biospecimens. The protocol outlines the fundamental aspects of how the collection, storage, and data management of specimens and related health information will be managed for the HCCTB. HCCTB will serve as the honest broker to other researchers that present with an separate valid IRB approval to utilize the specimens from the HCCTB.
To collect information about the patient's leukemia and to seek the optimal treatment for children with ALL based on the individual level of risk of the cancer coming back after treatment. The risk groups are defined as a result of recent research conducted by the Children’s Oncology Group (COG). We would like to learn if the use of an experimental intrathecal therapy (ITT), which has been given to many people with ALL and has been well tolerated, would be better at preventing relapse in the central nervous system and improve disease outcomes in children with High Risk ALL.
The purpose of this study is to test the effectiveness and safety of Gemcitabine and Pazopanib compared with Gemcitabine and Docetaxel in participants with soft tissue sarcoma. Screening tests will be done to ensure subjects are eligible to participate in this study. If the exams, tests and procedures show that subjects can be in the study, and they choose to take part, then they will be “randomized” into one of the two study groups: Group 1 or Group 2. Subjects in Group 1 will receive Gemcitabine 1000 mg/m2 intravenously (directly into a vein) on Day 1 and Day 8 and Pazopanib 800mg by mouth daily. Subjects in Group 2 will receive Gemcitabine 900 mg/m2 intravenouslyon Day 1 and Day 8 and Docetaxel 100 mg/m2 intravenously on Day 8. Both groups will be in 21 day cycles. Both groups will be asked to complete 2 “quality of life” questionnaires, on their first visit, then at 6 weeks (2nd cycle), 18 weeks (6th cycle) and at the end of study treatment. Subjects will be followed for up to 2 years.
The purpose of this research study is to compare overall survival and to compare the effects (good and bad) of stereotactic radiosurgery (SRS) to whole brain radiation therapy (WBRT) on the subject and their brain metastases.
To be eligible, the results of the MRI must show that the subject have at least one but no more than four brain metastases with one of the brain metastases resected. The study doctor must also verify that the subject meets other study requirements, such as not being pregnant. If the subjects are eligible and agree to participate, they will be randomized into one of the two treatment groups. The two treatment groups are: (Group A) whole brain radiation therapy (WBRT) and (Group B) stereotactic radiosurgery (SRS)
The study team would like to keep track of the subjects medical condition as long as the subject is alive or for a maximum of five years after the subject begins this study to look for any long-term effects of the treatment in this study.
This study is for subjects with Angiosarcoma that cannot be treated with surgery. The goal of this study is to find out what effects, good and/or bad, pazopanib has on you and your angiosarcoma. We do not know if treatment will help you.
• Your condition could get better
• There may be no effect on your condition
• Your condition may get worse
We can use what we learn from this study to help other people with the same disease. Screening procedures will be done to determine if subjects may be enrolled in the study. If subjects are eligible and are willing to participate, then subjects may begin treatment on the study. Subjects will be given the study drug in pill form and will take it every day with food. Subjects will take the study drug until their disease progresses, they have side effects or they decide to stop therapy. once subjects stop treatment, they will be followed for 2 or 3 months to see how they are doing.